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ABSTRACT
Although the spleen is frequently involved in disseminated non-Hodgkin’s lymphoma 
(NHL), splenic presentation as the initial or only site of disease is uncommon. Treatment 
modalities include surgery, chemotherapy, and radiation therapy. The priority of cancer 
follow up is to perform surveillance for recurrent cancer and evaluation of treatment 
response. Side effects of treatment are frequently missed or overlooked. A 66-year-old 
woman was presented to our hospital with a month history of spleen enlargement. On 
physical examination the spleen was palpated at Schuffner 2. Abdominal MSCT scan 
was suggestive of lymphoma. Surgery revealed adhesion and obstruction of the stomach. 
Biopsy and gastrojejunostomy shunting were done, but splenectomy was difficult. The 
pathology anatomy findings confirmed the diagnosis of diffuse non Hodgkin’s lymphoma 
large B-cell type. Immunohistochemistry showed positive CD3 and CD20. She underwent 
6 cycles of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone 
(RCHOP) chemotherapy. CT evaluation done 7 months later revealed that the hilus lienalis 
lymph nodes and spleen has decrease in size. However, a lumbosacral x-ray done due to 
back pain revealed metastasis on her 1st and 2nd lumbal spine. After a single fraction of 
radiotherapy, nausea, vomiting and abdominal distension occurred. A 3 position abdominal 
x-ray revealed signs of small bowel obstruction. After surgery she has received 9 cycles 
of zoledronic acid and remained in good condition and ambulatory. Splenic presentation 
as the initial or only site of non-Hodgkin’s lymphoma (NHL) is uncommon. Acute small 
bowel obstruction and fistula due to palliative radiation therapy for bone metastasis needs 
prompt and appropriate treatment.
ABSTRAK
Meskipun lien sering terlibat pada limfoma non-Hodgkin diseminata, keterlibatan lien 
sebagai awal penyakit atau satu-satunya organ yang terkena adalah jarang. Modalitas 
terapi meliputi pembedahan, kemoterapi, dan terapi radiasi. Prioritas follow up kanker 
adalah untuk melakukan surveilans pada kanker yang rekuren dan evaluasi respon terapi. 
Efek samping terapi seringkali tidak dikenali atau terlewat. Seorang wanita usia 66 tahun 
datang ke RS Sardjito dengan riwayat pembesaran lien sejak 1 bulan. Pada pemeriksaan 
palpasi didapatkan pembesaran lien sebesar Schuffner 2. MSCT scan abdomen dicurigai 
suatu limfoma. Pada saat pembedahan didapatkan obstruksi perut dengan pelekatan. 
Dilakukan biopsi dan shunt gastrojejunostomy, namun sulit dilakukan splenektomi. 
Pemeriksaan patologi anatomi mengkonfirmasi diagnosis limfoma non-Hodgkin tipe large 
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B-cell difus. Imunohistokimia menunjukkan CD3 dan CD20 positif. Pasien menjalani 6 
siklus kemoterapi dengan rituximab, siklofosfamid, adriamycin, vincristine, dan prednisolon 
(RCHOP). Evaluasi CT 7 bulan kemudian menunjukkan bahwa pembesaran limfonodi 
hillus lienalis dan lien berkurang. Namun demikian, foto x-ray lumbosakral yang dilakukan 
karena keluhan nyeri pinggang menunjukkan adanya metastasis pada vertebra lumbalis 
1 dan 2. Setelah dilakukan radioterapi fraksi tunggal, timbul mual, muntah, dan distensi 
abdomen. Foto x-ray abdomen 3 posisi menunjukkan tanda obstruksi usus kecil. Setelah 
dilakukan operasi, pasien menerima 9 siklus zoledronic acid dan menunjukkan kondisi 
baik. Manifestasi lien sebagai awal atau satu-satunya lokasi limfoma non-Hodgkin’s jarang 
dijumpai. Obstruksi usus kecil akut dan fistula yang disebabkan oleh terapi radiasi paliatif 
untuk metastasis tulang memerlukan terapi yang cepat dan tepat.
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INTRODUCTION
Non-Hodgkin’s lymphoma (NHL) is one 
of the most common cancers in the United 
States, accounting for about 4.3% of all 
new cancer cases. NHL is most frequently 
diagnosed among people aged 65-74.1 The 
most common subtype of NHL is diffuse large 
B-cell lymphoma (DLBCL), accounting for 
approximately 30% of cases.2 Although the 
spleen is frequently involved in disseminated 
NHL, splenic presentation as the initial or 
only site of disease is uncommon. The true 
incidence of splenic lymphoma is difficult to 
estimate because of the variable definition of 
this disease, however, the diagnosis of primary 
lymphoma of the spleen should be limited to 
involvement of only the spleen and splenic 
hilum.3 
A combination of rituximab and the 
cyclophosphamide, adriamycin, vincristine, 
and prednisolone (RCHOP) regimen has 
become the standard treatment for DLBCL 
because it greatly improves the outcome of 
patients with this disease, especially of young 
patients in the low-risk group.2 Radiotherapy 
is used in the treatment of NHL to improve 
outcomes of DLBCL patients who achieved 
a complete response (CR) to RCHOP.4 
Radiotherapy is also used in treatment of 
complication of the disease such as in bone 
metastases.5 Herein, we present the case 
of a primary splenic DLBCL patient who 
was treated with chemotherapy RCHOP. 
Complication of small bowel obstruction 
occurred after a single fraction of irradiation 
to treat bone metastases, which was detected 
by x-ray after 6 cycles of chemotherapy. The 
complication was treated via surgery.
CASE REPORT
A 66-year-old woman was presented to 
our hospital with a month history of spleen 
enlargement. On physical examination the 
spleen was palpated at Schuffner 2, with no 
other enlargement of lymph nodes. Abdominal 
MSCT scan was suggestive of lymphoma and 
confirmed that there was no paraaortic lymph 
node enlargement. There were intra and extra 
spleen hypodense lesions with indistinct 
border. The spleen’s remainder parenchyma 
showed slight enhancement. (FIGURE 
1). Surgery done 3 months later, revealed 
adhesion and obstruction of the stomach. 
Biopsy and gastrojejunostomy were done, but 
splenectomy was difficult to be performed. 
The pathology anatomy findings 
confirmed the diagnosis of diffuse non 
Hodgkin’s lymphoma large B-cell type. 
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Immunohistochemistry showed positive 
CD3 and CD20. She underwent 6 cycles of 
RCHOP chemotherapy. CT evaluation was 
done 7 months later showed that her hilus 
lienalis lymph nodes and spleen has decrease 
in size and was classified as Ann-Arbour 
stage IVS (FIGURE 2). She was admitted to 
the hospital due to back pain 2 weeks after 
her last evaluation. A lumbosacral radiograph 
revealed metastasis on her 1st and 2nd lumbal 
vertebrae. Radiotherapy was given once, but 
2 days after radiotherapy she complained 
of nausea and vomiting. The physical 
examination showed abdominal distension. 
A 3 position abdominal radiograph revealed 
coil spring, heringbone, short air-fluid level 
FIGURE 1. Abdominal CT scan before chemotherapy 
showing enlargement of spleen
and stepladder appearances, as signs of 
small bowel obstruction (FIGURE 3). She 
underwent surgery which revealed adhesion 
in the abdominal wall, a band which entrapped 
the illeum at about 80 cm from the ligament 
of Treitz, a grade 3 adhesion of jejunum to 
the ventral of abdomen and stomach, and a 
gaster-jejunum fistula which may be caused 
by radiation. Splenectomy was not able to be 
performed. After surgery, she has received 
9 cycles of zoledronic acid. On evaluation, 
the thoracic, lumbar, and sacral radiograph 
showed no signs of bone metastases. She was 
in good condition and ambulatory. Time of 
follow up was 30 months.
FIGURE 2. Abdominal CT scan after completion of 
chemotherapy showing a decreased spleen 
size
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FIGURE 3. Abdominal x-rays showing signs of small bowel obstruction
DISCUSSION
Primary splenic diffuse large B-cell lymphoma
Splenic involvement is found at initial 
presentation of lymphoma in 10–40% of 
patients with NHL. Splenic involvement is 
typically diffuse, and only a small minority 
of cases manifest nodules larger than 1 cm in 
diameter. Diffuse infiltration may be present in 
spleens of normal size. Marked splenomegaly 
almost always indicates infiltration.6 Primary 
splenic diffuse large B-cell lymphoma, an 
uncommon type of non-Hodgkin lymphoma, 
has been investigated only in small patient 
series before the rituximab era. Patients may 
present with abdominal pain, B symptoms, 
splenomegaly, splenic masses, and high lactate 
dehydrogenase (LDH) levels. As much as 61% 
had stage I or II disease. The diagnosis can 
be made by core-needle biopsy or diagnostic 
splenectomy. In patients with early-stage 
disease, splenectomy at diagnosis improves 
survival.7 Diagnosis of these lymphomas 
has been reliant on the histopathologic 
examination of the spleen.8
In our case, it seemed that the first 
presentation of the disease was enlargement of 
spleen without any evidence of involvement in 
other sites. Our patient’s diagnosis was made 
by biopsy of the spleen, but splenectomy at 
diagnosis was not done due to adhesion. 
However, a PET-CT was not done. PET-CT 
has been recommended for routine staging 
of FDG-avid, nodal lymphoma. In addition, 
splenic involvement is best determined 
by PET-CT and may be characterized 
by homogeneous splenomegaly, diffuse 
infiltration with milliary lesions, focal nodular 
lesions, or a large solitary mass. PET-CT leads 
to change in stage in 10% to 30% of patients, 
more often upstaging, although alteration in 
management occurs in fewer patients, with no 
demonstrated impact on overall outcome. As a 
result, diffuse large B-cell lymphoma patients 
can be spared a staging bone marrow biopsy, 
and a routine chest x-ray is unnecessary for 
staging.9
Role of chemotherapy on DLBCL
The treatment option for primary splenic 
DLBCL generally involves six to eight cycles 
of chemotherapy with the R-CHOP regimen 
(rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisone).10,2 For patients 
who are refractory to chemotherapy or are 
inoperable, therapeutic splenic irradiation 
(SI) might be a reasonable and possibly the 
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only treatment option with curative intention. 
However, the efficacy and safety of SI in 
treating primary splenic DLBCL remain 
uncertain and need further investigation.2 
Brox & Shustik suggests that the prognosis 
of NHL of the spleen, when pathologically 
staged, may have a favorable prognosis which 
approximates that seen with limited stage NHL 
at other sites.3splenic presentation as the initial 
or only site of disease is uncommon. The true 
incidence of splenic lymphoma is difficult to 
estimate because of the variable definition 
of this disease, however, the diagnosis of 
primary lymphoma of the spleen should be 
limited to involvement of only the spleen and 
splenic hilum. Using this restricted definition, 
our experience suggests that the prognosis 
of NHL of the spleen, when pathologically 
staged, may have a favorable prognosis which 
approximates that seen with limited stage 
NHL at other sites.  
Role of radiotherapy on DLBCL
Since the 20th century, radiotherapy (RT) 
has been used for treatment of symptomatic 
splenomegaly. Splenomegaly occurs in 
association with hematologic disorders. A 
study of 122 patients receiving 246 RT courses 
because of symptomatic splenomegaly 
revealed those who received RT were patients 
with chronic myelogenous leukemia (CML), 
chronic lymphocytic leukemia (CLL), 
osteomyelofibrosis (OMF), polycythemia 
vera (PV), acute myelogenous leukemia, 
idiopathic thrombocytopenic purpura (ITP), 
non-Hodgkin lymphoma (NHL), and multiple 
myeloma (MM). Patients were treated with 
Cobalt-60 gamma radiation or 5-15MV 
photons. The fraction size ranged from 10-200 
cGy and the total dose per treatment course 
from 30-1600 cGy. Significant pain relief was 
achieved for 74.8% of the RT courses given 
for splenic pain. At least 50% regression was 
attained for 77% of the RT courses given for 
SM. 36 patients died within 2 months due to 
the terminal nature of their disease. Of the RT 
courses applied for cytopenia, 73.6% achieved 
a significant improvement of hematological 
parameters and reduction of transfusion need. 
The present analysis documents the efficacy 
of RT.11 
A meta-analysis study supported the 
role of radiotherapy as an option for DLBCL 
patients who achieve a CR to RCHOP, 
especially those with bulky disease.4 Another 
systematic review with meta-analysis by Dos 
Santos et al.,12 showed that RT enhances 
progression free survival after chemotherapy 
with no impact on overall response rate and 
overall survival for aggressive and localized 
NHL.12 Another role for radiotherapy consists 
of palliative treatment for bone metastases to 
relieve pain, preserve functions, and maintain 
skeletal integrity. Other currently available 
pain-relieving strategies include opioid-based 
analgesia, bisphosphonates, and acupuncture. 
External beam radiotherapy (EBRT) can 
provide significant palliation of painful bone 
metastases in 50–80% of patients, with up to 
one-third of patients achieving complete pain 
relief at the treated site.5
The common the appropriate fractionation 
schemes can be divided as short-course and 
long-course. Jeremic et al., investigated the 
efficacies of three short-course RT regimens 
(4 Gy vs 6 Gy vs 8 Gy) in the treatment of 
painful bone metastasis and confirmed that 
8 Gy might be the lowest optimal single 
fraction.13 The long-course regimens usually 
include 30 Gy in 10 fractions, 20 Gy in 5 
fractions, 24 Gy in 6 fractions, etc. It has been 
reported that 30 Gy in 10 fractions is the most 
common scheme in the United States, 20 Gy 
in 5 fractions is the most common scheme in 
Canada, and a short-course scheme of 8 Gy 
in a single fraction remains most common in 
some European countries.5
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Zhu5 reviewed some prospective 
randomized trials that had compared the 
short-course or long-course regimens of 
palliative radiotherapy for painful bone 
metastases. Randomized trials from different 
areas in the world have demonstrated that 
single-fraction radiation therapy is sufficient 
to achieve palliation of painful bone 
metastases with optimized convenience for 
both patients and caregivers. A single dose of 
8 Gy seems to become the standard treatment. 
However, patients receiving short-course 
radiotherapy may receive remarkably more re-
irradiations.5,14the most common primary sites 
being breast, prostate, and lung. Important 
in palliative treatment is to reach a maximal 
effect with the minimal treatment. The aim of 
palliation for cancer patients is to increase the 
quality of their remaining life.Conclusions. 
The management of bone pain includes 
analgesics, local treatment (radiation, surgery A 
systematic review analyzing the effectiveness 
and safety of radiotherapy plus intravenous 
bisphosphonates versus radiotherapy alone 
for treating bone metastasis showed that 
the combine treatment radiotherapy plus 
intravenous bisphosphonates for bone 
metastases is safe and effective.15
Complications of radiotherapy on small 
bowel
Our patient underwent radiotherapy 
due to bone pain which was suspected to be 
caused by bone metastases on her 1st and 2nd 
lumbar spine. She has had radiotherapy once 
before small bowel obstruction occured. 
Surgery reports stated that there was a 
possibility that the gastro-jejunal fistula was 
caused by radiation. The adhesion however 
may be caused by the cancer or worsened by 
radiation to the bone (lumbar spine), since 
adhesions were already found on the initial 
biopsy surgery, but response to chemotherapy 
was noted by decreasing size of the spleen. 
Clinical manifestations of gastrointestinal 
radiation injury can present acutely during 
or soon following radiotherapy due to acute 
mucosal injury and inflammation or they 
can present insidiously within few months 
or years after radiotherapy due to a chronic 
process of transmural fibrosis and vascular 
sclerosis.16there is an increasing emphasis 
on the efficacy and safety aspects of cancer 
therapy. Radiation therapy is a common 
treatment for a wide variety of cancers, either 
alone or in combination with other treatments. 
Ionising radiation injury to the gastrointestinal 
tract is a frequent side effect of radiation 
therapy and a considerable proportion of 
patients suffer acute or chronic gastrointestinal 
symptoms as a result. These side effects often 
cause morbidity and may in some cases 
lower the efficacy of radiotherapy treatment. 
Radiation injury to the gastrointestinal tract 
can be minimised by either of two strategies: 
technical strategies which aim to physically 
shift radiation dose away from the normal 
intestinal tissues, and biological strategies 
which aim to modulate the normal tissue 
response to ionising radiation or to increase 
its resistance to it. Although considerable 
improvement in the safety of radiotherapy 
treatment has been achieved through the use 
of modern optimised planning and delivery 
techniques, biological techniques may offer 
additional further promise. Different agents 
have been used to prevent or minimize the 
severity of gastrointestinal injury induced 
by ionising radiation exposure, including 
biological, chemical and pharmacological 
agents. In this review we aim to discuss various 
technical strategies to prevent gastrointestinal 
injury during cancer radiotherapy, examine 
the different therapeutic options for acute and 
chronic gastrointestinal radiation injury and 
outline some examples of research directions 
and considerations for prevention at a pre-
clinical level.
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Acute radiation-induced small bowel 
disease usually presents with colicky 
abdominal pain, bloating, loss of appetite, 
nausea, diarrhea and fecal urgency during or 
shortly after a course of radiotherapy. Almost 
all patients receiving pelvic or abdominal 
radiotherapy experience some form of 
gastrointestinal symptoms. Patients usually 
notice these symptoms during the second 
week of treatment (when tissue damage and 
inflammation is probably at a maximum), 
and they characteristically peak by the fourth 
to fifth week (when histological changes are 
stable or improving).17
Obstruction usually affects the small 
bowel or, after pelvic radiotherapy, the 
sigmoid. Several factors may contribute 
in individual patients. It may develop as a 
result of benign causes such as changes in 
intestinal transit, medical causes, adhesions 
or radiotherapy-induced fibrosis, or malignant 
causes such as recurrent cancer or peritoneal 
carcinomatosis. Acute small bowel obstruction 
should be managed conservatively initially 
with analgesia, intravenous fluids, nutritional 
support and nasogastric aspiration unless 
there is suspicion of strangulation requiring 
emergency surgery. Cross-sectional imaging, 
which sometimes is difficult to interpret 
accurately, may be helpful to estimate the level 
of obstruction and whether it is complete or 
incomplete. The possibility of multiple sites 
of partial obstruction needs to be carefully 
considered as this may limit surgical options.18
Chronic small bowel radiation disease 
typically develops between 18 months and 6 
years after a completed course of radiotherapy, 
but has been reported to present up to 30 years 
later.17 Late radiation injury to the bowel, 
which may result in bleeding, frequency, 
fistula formation, and, particularly in small 
bowel, obstruction, is caused by damage to 
the entire thickness of the bowel wall.19the late 
effects of radiation on three gastrointestinal 
sites, the esophagus, the stomach, and the 
bowel, are described. Esophageal dysmotility 
and benign stricture following esophageal 
irradiation are predominantly a result of 
damage to the esophageal wall, although 
mucosal ulcerations also may persist following 
high-dose radiation. The major late morbidity 
following gastric irradiation is gastric 
ulceration caused by mucosal destruction. 
Late radiation injury to the bowel, which 
may result in bleeding, frequency, fistula 
formation, and, particularly in small bowel, 
obstruction, is caused by damage to the entire 
thickness of the bowel wall, and predisposing 
factors have been identified. For each site 
a description of the pathogenesis, clinical 
findings, and present management is offered. 
Simple and reproducible endpoint scales for 
late toxicity measurement were developed 
and are presented for each of the three 
gastrointestinal organs. Factors important 
in analyzing late complications and future 
considerations in evaluation and management 
of radiation-related gastrointestinal injury 
are discussed.”Int J Radiat Oncol Biol Phys. 
1995 Mar 30;31(5 Prostprandial pain, acute or 
intermittent small bowel obstruction, nausea, 
anorexia, weight loss, bloating, diarrhea, 
steatorrhea and malabsorption of selected 
or multiple nutrients, are also symptoms of 
chronic enteropathy. These can arise from 
damage to the small bowel itself or associated 
phenomena such as bile salt malabsorption, 
bacterial overgrowth or lactose intolerance.17
Deitel et al.,20 reported that hospitalization 
was required for intestinal injuries following 
radiotherapy for carcinoma of the cervix, 
endometrium, ovary, bladder, rectum, and 
other primary sites. Intestinal complications 
included stenosis, perforation, rectal ulcer, 
and rectovaginal, ileovaginal, and ileovesical 
fistula. Surgery, such as bowel resections, 
colostomy, adhesiolysis, ileocolic bypass, and 
Hartmann’s procedure for sigmoid perforation, 
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was indicated for some complications due to 
radiotherapy.20endometrium, ovary, bladder, 
rectum, and other primary sites. Intestinal 
complications included stenosis, perforation, 
rectal ulcer, and rectovaginal, ileovaginal, 
and ileovesical fistula; 27 patients had 
multiple intestinal complications. Operation 
was necessary in 33 patients, as follows: 
bowel resections, 18; colostomy alone, five; 
adhesiolysis, five; ileocolic bypass, three; 
and Hartmann’s procedure for sigmoid 
perforation, two. Five anastomotic leaks and 
six postoperative deaths occurred. Causes of 
death among the remaining patients included 
residual cancer (ten
CONCLUSION
Splenic presentation as the initial or only 
site of non-Hodgkin’s lymphoma (NHL) is 
uncommon. In our case, CT evaluation showed 
decrease in spleen size after chemotherapy. 
After 9 cycles of zoledronic acid, there were 
no signs of bone metastases on radiographic 
findings. However, response assessment using 
PET-CT as the preferred modality was not 
performed.
Radiotherapy to treat painful bone 
metastasis is needed to improve quality of 
life. However, complications should not be 
overlooked. In this case, acute small bowel 
injury due to radiation needs prompt treatment, 
obstruction was treated with surgery.
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